Woburn, MA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Azurity Pharmaceuticals, a privately held specialty pharmaceutical company, today highlighted continued momentum across its global business including a commercial presence in more than 50 countries and a diversified portfolio of medicines across 11 therapeutic areas. Building on a series of recent regulatory approvals, strategic partnerships, and portfolio investments, Azurity continues to accelerate access to medicines designed for the realities of everyday life.
Read more at globenewswire.comAzurity Pharmaceuticals Showcases Growth and Commercial Momentum ahead of CPHI Milan 2026
Barchart·09/29/2026 07:30:00
语音播报
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.